Key Insights

Highlights

Success Rate

95% trial completion (above average)

Research Maturity

57 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

2.6%

3 terminated out of 117 trials

Success Rate

95.0%

+8.5% vs benchmark

Late-Stage Pipeline

15%

17 trials in Phase 3/4

Results Transparency

14%

8 of 57 completed with results

Key Signals

8 with results95% success

Data Visualizations

Phase Distribution

71Total
Not Applicable (27)
Early P 1 (3)
P 1 (9)
P 2 (15)
P 3 (7)
P 4 (10)

Trial Status

Completed57
Recruiting30
Unknown13
Not Yet Recruiting8
Active Not Recruiting3
Terminated3

Trial Success Rate

95.0%

Benchmark: 86.5%

Based on 57 completed trials

Clinical Trials (117)

Showing 20 of 20 trials
NCT07286006Phase 2Enrolling By InvitationPrimary

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

NCT07018323Phase 2RecruitingPrimary

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT00001159Recruiting

Natural History of Thyroid Function Disorders

NCT07017907RecruitingPrimary

Evaluating an AI Tool for Detecting Thyrotoxic States

NCT07305818Phase 1RecruitingPrimary

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

NCT06980649Phase 1RecruitingPrimary

Study of BHV-1300 in Graves' Disease

NCT06984627Phase 2RecruitingPrimary

A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

NCT06727604Phase 2RecruitingPrimary

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT07596849Phase 3Not Yet RecruitingPrimary

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

NCT07570316Phase 3Not Yet Recruiting

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

NCT06921304Not ApplicableActive Not RecruitingPrimary

BASE-DIET: a Study on Nutritional Intervention in Patients With Graves' Disease

NCT07333677Early Phase 1RecruitingPrimary

In Vivo CAR-T for Refractory Graves' Disease

NCT07480720RecruitingPrimary

Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease

NCT07413874Not ApplicableNot Yet Recruiting

Telehealth Music Therapy for Adults With Endocrine Disorder and Depression

NCT07286656Phase 1Recruiting

A Study of GensSci098 in Subjects With Graves' Disease

NCT07410637Not ApplicableRecruitingPrimary

Impact of Thyroid Hormones on Human Glucose and Energy Metabolism

NCT05907668Phase 2CompletedPrimary

A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

NCT07369063Phase 2Recruiting

Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease

NCT07261345Early Phase 1RecruitingPrimary

Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease

NCT07046546Not ApplicableRecruiting

Thyroid Artery Goitre Embolization Trial A Pilot Study Investigating Thyroid Artery Embolisation as a Treatment for Large Thyroid Nodules

Scroll to load more

Research Network

Activity Timeline